Dendritic Cell Vaccine for Prostate Cancer
Dendritic cell vaccine for prostate cancer consists of autologous dendritic cells loaded with tumor-associated antigens and matured ex vivo for personalized cancer vaccination. This product is a cell therapy product under tariff item 3002.51.00, as it involves modified cell cultures for therapeutic use.
Import Duty Rates by Country of Origin
| Origin Country | MFN Tariff | Surtaxes | Total Effective Rate |
|---|---|---|---|
| 🇨🇳China | Free | — | Free |
| 🇲🇽Mexico | Free | — | Free |
| 🇺🇸United States | Free | — | Free |
| 🇩🇪Germany | Free | — | Free |
| 🇯🇵Japan | Free | — | Free |
More Specific Codes
This product may fall under a more specific subheading:
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right tariff item — and can price the duty on it in the same conversation.
Import Tips & Compliance
• Confirm that the product is classified as a cell therapy product and not as a vaccine under heading 30.02
• Provide evidence of the ex vivo maturation and antigen loading to CBSA
• Ensure compliance with Health Canada's Biologics and Genetic Therapies Directorate
Related Products under Tariff item 3002.51.00
CAR-T Cell Therapy for Leukemia
CAR-T cell therapy consists of patient-derived T-cells that are genetically modified to express chimeric antigen receptors targeting CD19-positive cancer cells. This personalized immunotherapy is used to treat relapsed B-cell acute lymphoblastic leukemia and falls under tariff item 3002.51.00 as a cell therapy product.
iPSC-Derived Cardiomyocyte Therapy for Heart Failure
iPSC-derived cardiomyocyte therapy involves induced pluripotent stem cells differentiated into cardiomyocytes for intramyocardial injection to repair heart tissue after myocardial infarction. These engineered cell cultures are classified under tariff item 3002.51.00 as cell therapy products.
Mesenchymal Stem Cell Therapy for Osteoarthritis
Mesenchymal stem cell therapy for osteoarthritis consists of allogeneic MSCs derived from umbilical cord tissue, expanded and cryopreserved for intra-articular injection. This product is a cell therapy product under tariff item 3002.51.00, as it involves modified cell cultures for therapeutic use.
NK Cell Therapy for Solid Tumors
NK cell therapy for solid tumors involves natural killer cells from peripheral blood that are cytokine-activated and expanded for adoptive transfer in cancer immunotherapy. These modified cell cultures are classified under tariff item 3002.51.00 as cell therapy products.
Treg Cell Therapy for Autoimmune Diseases
Treg cell therapy for autoimmune diseases consists of regulatory T-cells expanded ex vivo from patient blood and modified for enhanced suppressive function, used to treat graft-versus-host disease. This product is a cell therapy product under tariff item 3002.51.00, as it involves modified cell cultures for therapeutic use.